Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of NTX-1472 in Social Anxiety Disorder
Sponsor: Newleos Therapeutics, Inc.
Summary
The primary goal of this Phase 2 clinical trial is to determine the effects of a novel V1a receptor antagonist (NTX-1472) in adults with Social Anxiety Disorder (SAD). The main questions this trial aims to answer are: * Is NTX-1472 safe and well tolerated in adults with SAD? * How effectively does NTX-1472 treat adults with SAD? Researchers will compare the effects of NTX-1472 with matching placebo (a look-alike capsule that contains no drug). Participants will: * Take NTX-1472 or matching placebo every day for 8 weeks * Visit the clinic 6 times over the course of 14 weeks for checkups and tests
Official title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of NTX-1472, a V1a Receptor Antagonist, in Adults With Social Anxiety Disorder
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2025-12-09
Completion Date
2027-01
Last Updated
2026-01-21
Healthy Volunteers
No
Conditions
Interventions
NTX-1472
Daily (QD) x 8 weeks.
Placebo
Daily (QD) x 8 weeks.
Locations (11)
SOAR Clinical Study Site
Pheonix, Arizona, United States
SOAR Clinical Study Site
Encino, California, United States
SOAR Clinical Study Site
Los Angeles, California, United States
SOAR Clinical Study Site
Oceanside, California, United States
SOAR Clinical Study Site
San Jose, California, United States
SOAR Clinical Study Site
Jacksonville, Florida, United States
SOAR Clinical Study Site
Tampa, Florida, United States
SOAR Clinical Study Site
Boston, Massachusetts, United States
SOAR Clinical Study Site
Brooklyn, New York, United States
SOAR Clinical Study Site
Memphis, Tennessee, United States
SOAR Clinical Study Site
Austin, Texas, United States